Search company, investor...
Dicerna Pharmaceuticals company logo

Dicerna Pharmaceuticals

Founded Year



Take Private | Alive

Total Raised






About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals is a pharmaceutical company developing RNA interference (RNAi)-based therapeutics against genetically-defined targets in multiple disease areas, including cancer. Dicerna's therapeutic approach utilizes its Dicer Substrate siRNA (DsiRNA) molecules and EnCore drug delivery technologies to silence previously undruggable disease targets, offering a potential new treatment option for patients. Dicerna delivers its DsiRNA molecules to cancer cells using its EnCore lipid nanoparticle drug delivery technology. EnCore has been specifically engineered to accumulate in tumors and mediate efficient delivery of the DsiRNAs to the RNAi machinery in the cancer cell cytoplasm. Encore particles are well tolerated and manufactured using well-established unit operations to ensure commercial scalability.

Headquarters Location

480 Arsenal St Building 1, Suite 120

Watertown, Massachusetts, 02472,

United States


Missing: Dicerna Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Dicerna Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Dicerna Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Dicerna Pharmaceuticals is included in 4 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,904 items

Dicerna Pharmaceuticals Patents

Dicerna Pharmaceuticals has filed 116 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • RNA
  • MicroRNA
patents chart

Application Date

Grant Date


Related Topics




MicroRNA, RNA, Virus families, RNA interference, Molecular biology


Application Date


Grant Date



Related Topics

MicroRNA, RNA, Virus families, RNA interference, Molecular biology



Latest Dicerna Pharmaceuticals News

Nicotinamide Adenine Dinucleotide Market Set to Record Exponential Growth - Here’s Why | Exclusive InsightAce Report

Jun 6, 2023

SASWAD, PUNE, Pune, INDIA Jersey City, NJ, June 06, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytics Pvt. Ltd. announces the release of a market assessment report on the "Global Nicotinamide Adenine Dinucleotide Market  (Grade (Food, Pharmaceutical, And Others) And Application (Dietary Supplements, Pharmaceuticals, Anti-Aging Products And Others))- Market Outlook And Industry Analysis 2030" The Nicotinamide Adenine Dinucleotide Market Size is valued at 498.66 Million in 2022 and is predicted to reach 1472.98 Million by the year 2031 at a 13.05 % CAGR during the forecast period for 2023-2031. Numerous essential cellular activities, such as DNA repair, epigenetically regulated gene expression, intracellular calcium signaling, and immunological functions, depend on the essential pyridine nucleotide nicotinamide adenine dinucleotide (NAD+). Additionally, it serves as a crucial substrate and cofactor for various activities. NADH, a mitochondrial hormone that lengthens cell life cycles, is one of the most well-known NAD supplements in modern biological study (anti-aging). Free PDF Report Brochure @ The market for nicotinamide adenine dinucleotides is primarily driven by rising consumer demand for anti-aging goods and expanding understanding of NAD's benefits in boosting metabolism. Leading scientific studies into NAD's importance for human health are optimistic about the future of the substance. The product acceptance rate is also greatly influenced by ongoing R&D projects to enhance the impact of NADH or NAD+ on metabolism to provide therapeutic intervention in inflammatory illnesses. Recent Developments: • In December 2021, the acquisition of Dicerna Pharmaceuticals was completed, according to Novo Nordisk. Dicerna joined Novo Nordisk as a fully-owned subsidiary following the transaction. It will no longer be possible to list or trade Dicerna's common stock on the Nasdaq Global Select Market. • In December 2021, to market its specialty generic drugs in the Middle East, Biocon Ltd. collaborates with Tabuk Pharmaceuticals. The alliance will open the door for Biocon to expand into the MENA area, which will now include Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, and Iraq, in addition to Jordan and Lebanon. By building a robust worldwide portfolio of products—directly or via strategic partnerships—Biocon has reached yet another significant milestone demonstrating its dedication to serving patients worldwide with affordable drugs. Top Key Players in the Nicotinamide Adenine Dinucleotide Market: Bontac Bioengineering F. Hoffmann-La Roche Ltd OYC Americas, Inc. Shenzhen Hygieia Biotechnology Co., Ltd Zhejiang Dazhan Biotechnology Co., Ltd. Otto Chemie Pvt. Ltd.

Dicerna Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Dicerna Pharmaceuticals founded?

    Dicerna Pharmaceuticals was founded in 2007.

  • Where is Dicerna Pharmaceuticals's headquarters?

    Dicerna Pharmaceuticals's headquarters is located at 480 Arsenal St, Watertown.

  • What is Dicerna Pharmaceuticals's latest funding round?

    Dicerna Pharmaceuticals's latest funding round is Take Private.

  • How much did Dicerna Pharmaceuticals raise?

    Dicerna Pharmaceuticals raised a total of $123.8M.

  • Who are the investors of Dicerna Pharmaceuticals?

    Investors of Dicerna Pharmaceuticals include Novo Nordisk, Eli Lilly and Company, Oxford Bioscience Partners, Skyline Ventures, Abingworth and 10 more.

  • Who are Dicerna Pharmaceuticals's competitors?

    Competitors of Dicerna Pharmaceuticals include Sirnaomics, Cell Point, Agrisoma BioSciences, PhaseRx, Zevra Therapeutics, Vascular Biogenics, Calibrant Biosystems, Newron Pharmaceuticals, Bar Harbor BioTechnology, Advanced Cell Technology and 12 more.

Compare Dicerna Pharmaceuticals to Competitors

Targeted Cell Therapies

Targeted Cell Therapies (TCT) is a Massachusetts-based biopharmaceutical company that is using its powerful technology platform for the development of biotherapeutics for a broad range of human diseases. The technology permits the oral delivery of large molecules, avoiding the usual need for injection. The company's approach uses glucan particles containing nanoplexed nucleic acid (DNA or RNA) payloads encoding therapeutic molecules. Following oral administration, the glucan particles and their payload are rapidly taken up by macrophages in the small intestine. As the macrophages migrate to sites of inflammation or pathology, the payloads are processed by cellular machinery into active therapeutics. TCT believes that its orally administered therapeutics will be more efficacious and safer than the currently available injectables. Targeted Cell Therapies lead compound is for Gaucher Disease, the most common lysosomal storage disorder. Other targets for the company's biotherapeutics include lytic and low bone density conditions and inflammatory disorders.


Welgen, Inc. is a biotech company developing technologies and products for biomedical research. The company was founded in 2002 to develop vectors for gene delivery and silencing that facilitate research activities in both academia and industry. The company's products provide the medical research community and the pharmaceutical industry with rapid and cost-efficient approaches for gene function research and drug development.

Epeius Biotechnologies

Scientists at Epeius Biotechnologies have developed a targeted delivery system (TDS) that can transport genes or other therapeutic agents directly to diseased areas in the body. This pathotropic, or disease-seeking, technology has enabled the company to develop Rexin-G, a tumor-targeted, injectable gene delivery system that has demonstrated remarkable safety and single-agent efficacy in clinical trials internationally. Rexin-G is currently in clinical trials for pancreatic cancer in the U.S. ƒƒ‚ƒš‚" where it has achieved FDA orphan drug status ƒƒ‚ƒš‚" and has accelerated approval in the Philippines for the treatment of all solid tumors that are resistant to standard chemotherapy. The company's international clinical outreach with Rexin-G has enabled us to expedite further demonstrations that Rexin-G is highly active in a broad spectrum of chemo-resistant tumor types with efficacy and excellent safety profiles. The company are a biopharmaceutical company focused on expanding the therapeutic utility and commercialization of the company's pathotropic approach to disease treatment through internal development and commercialization of the company's oncology products and cancer vaccines, and through strategic partnerships in additional areas of oncology, immunology, cardiovascular, ocular, and wound healing applications, precision targeted diagnostics, and stem cell technologies.

Agrisoma BioSciences

Agrisoma Biosciences is an agricultural company that has commercialized carinata, a non-food oilseed crop designed for sustainable production of biofuels. Agrisoma sells carinata seed products under the Resonance brand name, and uses advanced crop improvement technologies to provide superior crop varieties to growers.

MOgene LC

MOgene is a biotechnology company, focused on understanding the mechanisms of cellular and organismal toxicity of chemical compounds and applying the knowledge to improve safety and efficacy of products across life science industries. MOgene uses a systems biology approach to understand gene function in the context of biological networks, to develop assays and biomarkers for molecular diagnostic solutions that would help address toxicity issues. MOgene is an Agilent-certified gene expression service provider and aims to provide microarray services including custom design of arrays, experiment design and detailed bioinformatics analysis.


TheraVasc is a privately-held biotechnology company with offices in Louisiana, focused on the development of vascular therapies with decreased risks through the repositioning of drugs with known safety profiles. The Company's first program is for the treatment of peripheral artery disease (PAD). PAD is a chronic disorder associated with reduced blood flow to the extremities, affecting some 14 million Americans and hundreds of millions of people across the world. This disease causes severe pain in the extremities, limiting mobility and in some cases, leads to death. Unfortunately, there are no treatments available for this disease. TheraVasc's lead product, TV1001i, selectively increases blood flow in ischemic tissues affected in PAD.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.